Melanoma, cutaneous malignant, susceptibility to, 2
MONDO:0007964Clinically atypical nevi (usually exceeding 5 mm in diameter and having variable pigmentation and ill defined borders) with an increased risk for development of non-familial cutaneous malignant melanoma. Biopsies show melanocytic dysplasia. Nevi are clinically and histologically identical to the precursor lesions for melanoma in the B-K mole syndrome. (Stedman, 25th ed)
Also known as: Atypical Mole syndrome, B-K Mole syndrome, dysplastic nevus syndrome, familial dysplastic nevi, melanoma, cutaneous malignant, 2, melanoma, cutaneous malignant, susceptibility to, 2, melanoma, cutaneous malignant, susceptibility to, type 2, CMM2
38 clinical trials for this condition and its sub-types, 6 tagged with Melanoma, cutaneous malignant, susceptibility to, 2 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Pancreas cancer screening trial enrolls 9,000 High-Risk individuals
Diagnosis Recruiting nowThis Phase 3 study is testing whether markers in pancreatic fluid and blood can detect early pancreas cancer in people with high genetic risk. Participants receive a secretin injection to collect fluid during an endoscopy. The goal is to improve early detection in those with here…
Phase 3 • Sponsor: Johns Hopkins University • Aim: Diagnosis
Last updated Jun 27, 2026 07:54 UTC
-
Could your genes raise your melanoma risk? new study seeks answers
Knowledge-focused Recruiting nowThis study aims to understand how genetics and environmental factors contribute to melanoma, a serious skin cancer. Researchers will enroll up to 3,000 people with a personal or family history of melanoma or related conditions. Participants will fill out questionnaires, provide b…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Melanoma Drug's hidden effect on moles under microscope
Knowledge-focused Recruiting nowThis study looks at how a standard immunotherapy drug (anti-PD1) changes the appearance and biology of atypical moles in people with advanced melanoma. Researchers will track 30 patients to see if the drug alters mole size, color, and cellular features. The goal is to better unde…
Sponsor: John Kirkwood • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC